An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Camrelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Sep 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2018.
- 07 Sep 2018 Status changed from active, no longer recruiting to recruiting.
- 07 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.